Hepion Pharmaceuticals, Inc. (HEPA) announced that its Board of Directors appointed James Liddy as a director, effective August 19, 2026. The company states there are no arrangements or understandings with any other person regarding his selection and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
The report is signed on behalf of Hepion Pharmaceuticals by Gary Stetz, Interim Chief Executive Officer, dated August 20, 2026. No financial results or transactional developments are included in this disclosure; it is focused on corporate governance and board composition.
Hepion Pharmaceuticals, Inc. (HEPA) had a Schedule 13D filed by director and Chief Operating Officer Sireesh Appajosyula, reporting beneficial ownership of 5,250,000 shares of common stock, including 2,000,000 shares issuable upon exercise of warrants. This represents 5.7% of Hepion’s common stock, based on 90,219,317 shares outstanding as of August 10, 2026.
The filing states an aggregate purchase price of approximately $150,000 for the securities. On April 21, 2026 he acquired 1,250,000 shares for $50,000, and on July 31, 2026 he acquired 2,000,000 shares plus a warrant for 2,000,000 shares for $100,000. The warrant is immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation. The stake is described as acquired for investment purposes, with no additional specific corporate plans disclosed.
Hepion Pharmaceuticals, Inc. (HEPA) is the subject of an amended Schedule 13D reporting that a group led by Executive Chairman Vincent LoPriore, together with Gravitas Capital LP and Invictus Capital Advisors Pension Plan, beneficially owns 26,250,000 shares of common stock, or 26.2% of the class, based on 90,219,317 shares outstanding as of August 10, 2026.
This amount includes 10,000,000 shares issuable upon exercise of warrants with an exercise price of $0.06 per share, subject to a Beneficial Ownership Limitation. The group acquired shares and warrants for an aggregate purchase price of approximately $750,000 under Securities Purchase Agreements dated April 21 and July 31, 2026, and states the holdings were acquired for investment purposes.
Hepion Pharmaceuticals, Inc. (HEPA) is the subject of a Schedule 13D reporting that director and interim Chief Executive Officer Gary Stetz beneficially owns 5,250,000 shares of Common Stock, representing 5.7% of the class, based on 90,219,317 shares outstanding as of August 10, 2026.
The beneficial ownership includes 2,000,000 shares issuable upon exercise of warrants. In 2026, Stetz purchased 1,250,000 shares for $50,000 and 2,000,000 shares plus a warrant for 2,000,000 shares for $100,000. The warrant is immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation. The stake is reported as acquired for investment purposes, and he may acquire additional shares over time.
Hepion Pharmaceuticals, Inc. reports no revenue for the three and six months ended June 30, 2026 as it transitions from drug development to liver disease diagnostics. The company recorded a net loss of $1.25 million for the quarter and $2.06 million for the first half of 2026, a substantial improvement from a $7.15 million loss in the prior-year six‑month period, driven by lower operating expenses and a much smaller loss from warrant revaluation.
At June 30, 2026, cash was $1.63 million, total assets were $1.93 million, liabilities $0.65 million and stockholders’ equity $1.28 million, with working capital of $1.4 million. Management states there is substantial doubt about the ability to continue as a going concern without additional capital. After quarter‑end, Hepion raised $3.1 million in a July 2026 private placement of 61.1 million common shares and warrants and had 90,219,317 common shares outstanding as of August 10, 2026.
The company licensed liver disease diagnostic assets from Cirna Diagnostics for a $70,000 upfront payment, with potential milestones and low single‑digit royalties, and terminated a prior New Day license, recovering 346,020 shares. Material weaknesses in internal control over financial reporting are disclosed, including insufficient personnel and weak controls over complex transactions and income tax reporting, with remediation plans dependent on raising further capital.
Hepion Pharmaceuticals, Inc. director Gary S. Stetz II reported net purchases on August 3, 2026. He acquired 500,000 shares of Common Stock at a price of $0.05 per share, bringing his direct Common Stock holdings to 500,000 shares. He also acquired warrants for 500,000 shares of Common Stock with an exercise price of $0.06 and an expiration date of August 3, 2031, resulting in 500,000 warrants held directly. The Rule 10b5-1 checkbox was not marked, indicating these purchases were not reported as made under a trading plan.
Hepion Pharmaceuticals, Inc. reporting person Gary S. Stetz, Interim CEO and director, reported two purchases on August 3, 2026. He acquired 2,000,000 warrants, each exercisable at $0.06 per share into common stock until August 3, 2031. He also purchased 2,000,000 shares of common stock at $0.05 per share, bringing his directly held common stock position to 3,250,000 shares.
Hepion Pharmaceuticals director Michael J. Purcell reported significant insider purchases. On 2026-08-03, he bought 2,000,000 shares of common stock at $0.05 per share, increasing his direct common stock holdings to 3,250,000 shares. He also purchased 2,000,000 warrants with an exercise price of $0.06 per share, exercisable into 2,000,000 common shares and expiring on 2031-08-03, leaving him holding 2,000,000 warrants after the transaction.
Hepion Pharmaceuticals, Inc. director and Chief Operating Officer Sireesh Appajosyula reported insider purchases on 2026-08-03. He acquired 2,000,000 common shares at $0.05 per share and 2,000,000 warrants with a $0.06 exercise price, expiring 2031-08-03. Following these trades, he directly owns 3,250,000 common shares and 2,000,000 warrants. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
Hepion Pharmaceuticals Executive Chairman Vincent S. LoPriore, through entities he controls, reported purchases totaling 20,000,000 HEPA-related securities on August 3, 2026. Gravitas Capital LP and Invictus Capital Advisors Pension Plan bought 10,000,000 warrants with a $0.06 exercise price and 10,000,000 common shares at $0.05 per share, all held as indirect ownership.